Search Site

Zilico Limited

Zilico's Approach to Cancer Screening

Zilico is focussed on developing a range of products that utilise Electical Impedance Spectroscopy (EIS) as a platform technology to provide diagnostics for certain cancers. 

  • EIS is a well-established technique in the public domain that examines tissue structure and so can identify changes that are associated with progression to cancer
  • Work at  the University of Sheffield and the Department of Medical Physics and Clinical Engineering at Sheffield Teaching Hospitals NHS Foundation Trust has focussed on using EIS to differentiate between normal, pre-cancerous and cancerous cells of the cervical epithelium
  • Zilico has refined and developed the EIS application for cervical cancer to provide a tool for clinicians to deliver better clinical management of patients improving the accuracy of colposcopy
  • EIS is applicable to a wide range of other cancers and Zilico has completed a proof of concept clinical study involving 50 patients with oral neoplasia